pepinemab + pembrolizumab
VX15/2503-12
Phase 2 small_molecule completed
Quick answer
pepinemab + pembrolizumab for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC) is a Phase 2 program (small_molecule) at VACCINEX, INC. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- VACCINEX, INC.
- Indication
- Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC)
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- completed